October 13, 2016

Update on Biologics Litigation and IPRs

As the popularity of biosimilars continues to grow in the United States, biosimilar and biologics manufacturers have begun testing the bounds of the BPCIA statute in district court litigation. In addition, biosimilar manufacturers have also turned to IPR proceedings to challenge patents covering biologic drugs.

Fish attorneys Gwilym Attwell and Michael Amon presented the following recent developments:

  • Recent district court cases and their impact on the biosimilars industry
  • IPRs challenging biologic patents
  • Strategies for biologics litigation

Gwilym Attwell, Principal
Michael Amon, Principal
No Comments

Sorry, the comment form is closed at this time.

Fill out the form below to receive our monthly newsletter and updates on your selected areas of interest. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of the email.

  • Fish & Richardson P.C. is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the services you requested from us. From time to time, we would like to contact you about our services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.
  • In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.
  • You can unsubscribe from these communications at any time. This can be done by clicking the unsubscribe link at the bottom of marketing emails you receive from us, or by emailing stating that you would like to be unsubscribed.
  • This field is for validation purposes and should be left unchanged.